Vermillion Appoints Dr. Judith K. Wolf as Chief Medical Officer

Jun 17, 2014, 16:01 ET from Vermillion, Inc.

AUSTIN, Texas, June 17, 2014 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, has appointed Dr. Judith K. Wolf to the new position of chief medical officer, effective September 15, 2014.

Dr. Wolf is a highly accomplished, widely published and active professional in the field of gynecologic cancer. Over the last eight years, she has held numerous academic and administrative positions at the University of Texas and Banner MD Anderson Cancer Centers, and currently serves as the division chief of Surgical Oncology and vice chair of the Department of Oncology Services at the Banner MD Anderson Cancer Center in Arizona.

"Dr. Wolf is an ideal fit for our expanding team of professionals," said James LaFrance, Vermillion's chairman, president and CEO. "She has pursued an exemplary career as a surgeon, administrator and patient advocate in gynecological health, and her clinical knowledge, professional organization skills and leadership abilities will be a tremendous asset as we work toward increasing awareness and adoption of OVA1."

Dr. Wolf has co-authored 94 peer-reviewed research articles and was the principal investigator or co-investigator for 11 research grants related to gynecologic cancers. She has served as the principal investigator, co-principal investigator or collaborator on 84 protocols, and has presented at more than 50 conferences, as well as at numerous scientific exhibitions and seminars. 

Dr. Wolf is also presently an adjunct professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center, and a clinical professor of Division of Clinical Education at Arizona College of Osteopathic Medicine. She is also chairman of the Medical and Scientific Advisory Board of the National Ovarian Cancer Coalition, and a member of the American Association of Cancer Research, Felix Rutledge Society, Society of Gynecologic Oncology and American Society of Clinical Oncology. Additionally, she is a fellow at the American College of Obstetrics and Gynecology.

Dr. Wolf received her medical degree at Northeastern Ohio Universities College of Medicine and Masters in Biomedical Sciences at The University of Texas Health Science Center in Houston. She completed her residency in obstetrics and gynecology at University of Texas Health Science Center in San Antonio, and fellowships in gynecologic surgery at University of Minnesota and MD Anderson. She is certified by the American Board of Obstetrics and Gynecology with a special qualification in gynecologic oncology.

About Vermillion Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit

Forward-Looking Statements This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the activities of ASPiRA LABS, Inc., Vermillion's future revenue and Vermillion's expected cash outlay. Words such as "may," "expects," "intends," "anticipates," "believes," "estimates," "plans," "seeks," "could," "should," "continue," "will," "potential," "projects" and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on Vermillion's expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ from those projected in such forward-looking statements include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products or otherwise comply with applicable laws and regulations; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third-party payers such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty regarding Vermillion's ability to generate sufficient demand for ASPiRA LABS' services to cover the laboratory's operating costs; (7) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (8) other factors that are described in Vermillion's Form 10-K for the year ended December 31, 2013 and Vermillion's Form 10-Q for the quarter ended March 31, 2014 filed with the Securities and Exchange Commission (the "SEC"). Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at

Investor Relations Contact: Liolios Group, Inc. Ron Both  Tel 1-949-574-3860

SOURCE Vermillion, Inc.